Hepatitis B vaccination: a clinical trial of the yeast derived recombinant DNA hepatitis B vaccine

A clinical trial to evaluate the protective efficacy of the yeast derived recombinant-DNA hepatitis B vaccine in Sharjah has shown that 21 of the 23 subjects vaccinated acquired significant titers of hepatitis B surface antibody protective against the infection. The two subjects who faiIed to respond were vaccinated in the gluteal region. No adverse reactions to the vaccine were reported during the trial. The yeast derived recombinant-DNA hepatitis B vaccine is an effective, safe and reliable measure of controlling hepatitis B